Andere Sprachen Virpax Pharmaceuticals, Inc.

Aktien

A404GA

US9282512063

VRPX

Verzögert Nasdaq Andere Börsenplätze 18:10:25 29.04.2024			% 5 Tage	% 1. Jan.
2,85 ^USD	-8,06 %		-13,64 %	-10,97 %

26.03.	Virpax Pharmaceuticals, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
15.03.	Scilex einigt sich mit Virpax auf $6 Millionen, 6% Lizenzgebühren für drei Medikamente	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Virpax Pharmaceuticals Reports 2023 Year-End Results	26.03.
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	15.03.
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price	28.02.
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price	27.02.
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.	27.02.
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research	07.02.
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research	07.02.
Virpax Pharmaceuticals Stockholders Approve Reverse Stock Split Plan; Shares Fall	29.12.
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting	29.12.
Virpax Pharmaceuticals : Failure to Satisfy Listing Rule - Form 8-K	13.12.
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing	20.11.
Virpax Pharmaceuticals Announces Leadership Transition	20.11.
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing	17.11.
Virpax Pharmaceuticals Announces Leadership Transition	17.11.
Virpax Pharmaceuticals Announces Leadership Transition	17.11.
Virpax Pharmaceuticals, Inc. Announces CEO Changes	17.11.
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16.11.
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments	15.11.
Virpax Pharmaceuticals Announces that Envelta Remains on Track for Trial in Humans Following FDA Review	01.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Virpax Pharmaceuticals, Inc.

Aktien

A404GA

US9282512063

VRPX

Andere Sprachen

Filter